**Core tip:** Role of photodynamic therapy (PDT) in unresectable cholangiocarcinoma has been scarcely described in the past. However most of these studies included patients who also underwent additional palliative measures simultaneously. Hence, overall safety and efficacy of photodynamic therapy is not clear. This is the first systematic review and meta-analysis evaluating exclusively the role of PDT in these patients. PDT with biliary stenting was compared to biliary stenting (BS) alone. PDT seems to be relatively safe and significantly superior to BS alone in this patient population.

INTRODUCTION
============

Cholangiocarcinoma is the primary cancer of bile ducts. It is an aggressive disease with dismal prognosis. It is a rare cancer comprising less than 2% of all cancers but the incidence has been increasing in the past decade\[[@B1]\]. Approximately 60%-70% of these tumors are located within 2 cm from the bifurcation of the common bile duct (hilar cholangiocarcinoma, also called Klatskin tumor), extrahepatic cholangiocarcinoma occur in approximately 20%-30% and intrahepatic in the remaining 5%-10%.

Bismuth-Corelette system is used to classify hilar cholangiocarcinoma into four types (Type I-IV). Bismuth Type I is limited to the common hepatic duct below the confluence of the right and left hepatic duct, Type II involves tumor infiltration at the confluence without communication between left and right hepatic ducts, Type III involves tumor extension into one main hepatic duct and the secondary bile ducts, Type IV involves bilateral hepatic ducts and the secondary intrahepatic ducts. It is asymptomatic in the early stages and difficult to diagnose.

Complete tumor resection with negative margins (R0) is the only curative option but only 20%-30% of patients are candidates for curative resection\[[@B2],[@B3]\]. Five year survival rates after curative R0 resection is about 30%-50%\[[@B2]-[@B7]\]. The remaining 70%-80% present at an advanced stage and are nonresectable due to locally advanced disease (Involvement of vessels or bilateral extension beyond secondary radicals) or presence of distant metastases\[[@B3],[@B8],[@B9]\].

Palliation is the primary management option in these patients. Chemotherapy and radiotherapy have limited role and do not prolong life in advanced cholangiocarcinoma\[[@B10]\]. Palliative biliary decompression by transpapillary or percutaneous insertion of biliary stent alleviates obstructive cholestasis and is currently the standard of care\[^11-17\]^. However, stent patency rates are limited by tumor ingrowth or overgrowth\[[@B18]-[@B22]\]. Most patients die from complications of obstructive cholestasis such as cholangitis, biliary sepsis or liver failure.

Photodynamic therapy (PDT) is a new local-ablative, tumor-specific treatment that has shown promising results and is now the standard of care for nonresectable cholangiocarcinoma\[[@B23]-[@B26]\]. PDT involves administration of a photosensitizing drug with affinity for neoplastic tissue and subsequent selective irradiation with light of a defined wavelength. The resulting interaction between light and photosensitizing agent causes death of tumor cells, and neovascular cells by formation of oxygen free radicals\[[@B27]-[@B29]\].

The first case of successful PDT for non resectable cholangiocarcinoma was described by McCaughan et al\[[@B30]\] in 1991. Many studies have since then confirmed the significant advantage of using PDT in patients with nonresectable Cholangiocarcinoma. Most of these studies included patients that additionally received other palliative treatments (surgery, radiotherapy, chemotherapy)\[[@B23],[@B24]\]. The aim of this study is to evaluate the success of photodynamic therapy exclusively, and its impact on survival, morbidity, biliary drainage and quality of life in patients with nonresectable cholangiocarcinoma through a systematic review and meta-analysis of the literature.

MATERIALS AND METHODS
=====================

Study selection criteria
------------------------

Studies evaluating the role of PDT as a palliative option in patients with advanced non-resectable cholangiocarcinoma, were included in this meta-analysis. Prospective studies, retrospective studies and randomized controlled trials (RCTs) were included. Subgroup analysis was performed on prospective studies to negate the heterogeneity introduced by retrospective studies. Studies that used PDT as a neo-adjuvant therapy in patients with resectable cholangiocarcinoma were excluded. Studies that used chemotherapy or radiation therapy along with PDT in patients with resectable or unresectable cholangiocarcinoma were excluded. Studies without original data, perspective articles review articles, and expert opinions were excluded from this meta-analysis. Only full text articles, peer reviewed and published in international journals were included in this analysis. If there were duplicate studies, the most complete and latest study was included in this meta-analysis.

Data collection and extraction
------------------------------

The study design was written in accordance to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement\[[@B31]\]. Articles were systematically searched in Medline, PubMed, Ovid journals, EMABSE, Cumulative Index for Nursing and Allied Health Literature, ACP journal club, DARE, International Pharmaceutical Abstracts, old Medline, Medline nonindexed citations, OVID Healthstar, and Cochrane Central Register of Controlled Trials (CENTRAL). The search was performed for the years 1966 to May 2016. Abstracts were manually searched in the major gastroenterology journals for the past 3 years. Study authors for the abstracts included in this analysis were contacted when the required data for the outcome measures could not be determined from the publications. The MeSH search headings used were "photodynamic therapy", "PDT", "cholangiocarcinoma", "hilar malignancy", "percutaneous trans-hepatic biliary drainage", "malignant biliary obstruction", "biliary drainage", "endoscopic biliary drainage". The reference lists of the included studies were manually searched for any relevant publications. Two authors (HM and VM) independently searched and extracted the data into an abstraction form. Any differences were resolved by mutual agreement. If the disagreement persisted, the final decision was made by a third author (AD) after reviewing the relevant information. The agreement between reviewers for the collected data was quantified using the Cohen's κ\[[@B32]\]. Data was extracted from the selected studies and entered into a standardized data collection form. The following variables were recorded: name and year of study; type of study; median age; male/female distribution; total number of patient included; number of patients that had PDT along with biliary stenting; number of patients that underwent biliary stenting only; PDT agent, PDT route, stent type - metal *vs* plastic, post treatment survival in PDT plus stenting group (in days), post treatment survival in biliary stenting group, over all adverse events (hepatic abscess/cholangitis/perihepatic abscess/drain site infection, photosensitivity) in both groups, cholangitis in both groups, photosensitivity in PDT group, Karnofsky performance scores (pre-treatment, post treatment and change in score after treatment) in both groups, median number of PDT sessions per patient in each study, bilirubin levels scores (pre-treatment, post treatment and change in score after treatment) in both groups.

Definitions
-----------

Successful biliary drainage was defined as a reduction in serum total bilirubin \> 50 % at 2 wk and to a value below 3.0 mg/dL at 4 wk follow up. Technical success was defined as successfully placed stent in the appropriate location, confirmed radiographically and/or endoscopically. Stent patency is defined as time interval between biliary stent insertion and the need for an un-anticipated re-interventions.

Quality of studies
------------------

Clinical trials designed with a control and treatment arms can be assessed for quality of the study. A number of criteria have been used to assess this quality of a study (*e.g*., randomization, selection bias of the arms in the study, concealment of allocation, and blinding of outcome). Jadad score was used to evaluate the quality of randomized studies. Cochrane Collaborations and the Quality of Reporting of Meta-analysis guidelines were followed to assess the quality of studies\[[@B33],[@B34]\]. Quality of retrospective studies were assessed using Newcastle-Ottawa Scale\[[@B35]\].

Statistical analysis
--------------------

This meta-analysis was performed by calculating pooled proportions. First the individual study proportion of survival (in days), adverse events, Karnofsky scores *etc*., were transformed into a quantity using Freeman-Tukey variant of the arcsine square root transformed proportion. The pooled proportion is calculated as the back-transform of the weighted mean of the transformed proportions, using inverse arcsine variance weights for the fixed effects model and DerSimonian-Laird weights for the random effects model\[[@B36],[@B37]\]. Random effects model was used if the heterogeneity was significant, and fixed effects model was used if heterogeneity was non-significant. Forest plots were drawn to show the point estimates in each study in relation to the summary pooled estimate. The width of the point estimates in the Forest plots indicates the assigned weight to that study. The heterogeneity among studies was tested using *I*^2^ statistic and Cochran's *Q* test based upon inverse variance weights\[[@B38]\]. *I*^2^ of 0%-39% was considered as non-significant heterogeneity, 40%-75% as moderate heterogeneity, and 76%-100% as considerable heterogeneity. If *P* value is \> 0.10, it rejects the null hypothesis that the studies are heterogeneous. The effect of publication and selection bias on the summary estimates was tested by both Harbord-Egger bias indicator\[[@B39]\] and Begg bias indicator\[[@B40]\]. Also, funnel plots were constructed to evaluate potential publication bias\[[@B41],[@B42]\]. Microsoft Excel 2013 software was used to perform statistics for this meta-analysis. Subgroup analysis was performed on only prospective studies.

RESULTS
=======

Study selection
---------------

Initial search identified 162 reference articles, in which 73 articles were selected and reviewed. Data was extracted from 10 studies\[[@B43]-[@B52]\] (*n* = 402) which met the inclusion criterion. All the studies are published as full text articles. Figure [1](#F1){ref-type="fig"} shows the flow diagram of search results. Among the 10 studies included in this analysis, only two were RCTs\[[@B43],[@B48]\]. Three studies\[[@B45],[@B50],[@B51]\] out of the 10 studies were retrospective studies and the rest were prospective studies\[[@B44],[@B46],[@B47],[@B49],[@B52]\]. Subgroup analysis was performed on all prospective trials.

![Study selection. PDT: Photodynamic therapy.](WJG-23-1278-g001){#F1}

The total number of patients included in this meta-analysis is 402, with a predominantly male population (65%). Median age of the patients was 68 years. Table [1](#T1){ref-type="table"} shows the baseline characteristics of the studies. The *P* for χ^2^ heterogeneity for all the pooled accuracy estimates was \> 0.10. The agreement between reviewers for the collected data gave a Cohen\'s κ value of 1.0.

###### 

Characteristics of included studies

  **Study**                          **Type**   ***n***   **PDT, *n***   **BS, *n***   **M/F**   **Age**   **Cancer type**      **PDT agent**       **PDT route**                **Stenting route**              **Stent type**                         **PDT sessions per patient**
  ---------------------------------- ---------- --------- -------------- ------------- --------- --------- -------------------- ------------------- ---------------------------- ------------------------------- -------------------------------------- ------------------------------
  Ortner et al\[[@B43]\], 2003       RCT        39        20             19            NA        66        Non resectable CCA   Photofrin 2 mg/kg   Endoscopic                   EBD or PTBD - Double stenting   Plastic                                2
  Dumoulin et al\[[@B44]\], 2003     P          44        24             20            19/25     77        Non resectable CCA   Photofrin 2 mg/kg   Endoscopic                   EBD or PTBD                     Plastic followed by metal 4 wk later   NA
  Cheon et al\[[@B45]\], 2004        R          47        27             20            38/9      63        Non resectable CCA   Photogem            Endoscopic                   PTBD in PDT, EBD in other       Plastic                                2
  Wiedmann et al\[[@B46]\], 2004     P          23        23             NA            15/8      68        Non resectable CCA   Photofrin 2 mg/kg   Endoscopic                   EBD or PTBD                     Plastic or Metal                       3
  Shim et al\[[@B47]\], 2005         P          24        24             NA            NA        58        Non resectable CCA   Photofrin 2 mg/kg   Percutaneous                 PTBD                            Plastic                                2
  Zoepf et al\[[@B48]\], 2005        RCT        32        16             16            20/12     68        Non resectable CCA   Photosan-3          Endoscopic or percutaneous   EBD or PTBD                     Plastic                                2
  Witzigmann et al\[[@B49]\], 2006   P          124       68             56            59/65     69        Non resectable CCA   Photofrin 2 mg/kg   Endoscopic                   EBD or PTBD                     Plastic                                2
  Prasad et al\[[@B50]\], 2007       R          25        25             NA            20/5      64        Non resectable CCA   Photofrin 2 mg/kg   Endoscopic or percutaneous   PTBD                            Plastic                                1
  Lee et al\[[@B51]\], 2012          R          33        18             15            24/9      66        Non resectable CCA   Photofrin 2 mg/kg   Endoscopic or percutaneous   EBD or PTBD                     Metal                                  1
  Wagner et al\[[@B52]\], 2013       P          11        11             NA            8/3       76        Non resectable CCA   Temoporfin          Endoscopic                   EBD or PTBD                     Plastic                                1

PDT: Photodynamic therapy; BS: Biliary stenting group; EBD: Endoscopic biliary drainage; PTBD: Percutaneous transhepatic biliary drainage; CCA: Cholangiocarcinoma; RCT: Randomized controlled trial; P: Prospective study; R: Retrospective study; NA: Not available.

Studies evaluating survival of patients followed up with the patients till death. Studies describing the adverse events and quality of life had a median follow up period of three months. All except three studies used Photofrin 2 mg/kg as the PDT agent. Photogem\[[@B45]\], Photosan-3\[[@B48]\], and Temoporfin\[[@B52]\] were the three other PDT agents used. PDT was administered via endoscopic route in six studies\[[@B43]-[@B46],[@B49],[@B52]\], percutaneous route in one study\[[@B47]\], and endoscopic or percutaneous route in three studies\[[@B48],[@B50],[@B51]\]. Biliary stenting was performed by endoscopic route (EBD) or percutaneous tranhepatic route (PTBD) in eight studies\[[@B43]-[@B46],[@B48],[@B49],[@B51],[@B52]\]. Two studies exclusively used PTBD for biliary drainage\[[@B47],[@B50]\]. Seven studies used plastic biliary stents, one study used only metal stents\[[@B43],[@B45],[@B47]-[@B50],[@B52]\], one study used metal and plastic stents\[[@B46]\], and one study used plastic stent followed by metal stent\[[@B44]\]. Median number of PDT sessions per patient was two.

Survival benefit and Quality of life with photodynamic therapy
--------------------------------------------------------------

Data was available in all the ten included studies, to calculate survival period. In the pooled patient population, the survival periods in PDT group (patient received PDT along with biliary stenting) and biliary stenting only group (BS group) were 413.04 d (95%CI: 349.54-476.54) and 183.41 days (95%CI: 136.81 to 230.02) respectively. *I*² (inconsistency) = 85.1% (95%CI: 73.5%-90.2%). Egger: bias = 5.09 (95%CI: 2.12-8.07), *P =* 0.0043. Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} are forest plot and funnel plot representing the survival in PDT group. Six out of ten studies\[[@B43],[@B46]-[@B49],[@B52]\] included data regarding Karnofsky performance scores. The change in Karnofsky performance scores after intervention in PDT and BS groups were +6.99 (95%CI: 4.15-9.82) and -3.93 (95%CI: -8.63-0.77) respectively. *I*² (inconsistency) = 97.6% (95%CI: 96.7%-98.1%). Egger: bias = 7.66 (95%CI: -0.22-15.53) *P =* 0.054. Figure [4](#F4){ref-type="fig"} is a forest plot representing the change in Karnofsky scores in PDT group.
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Biliary drainage outcomes with photodynamic therapy
---------------------------------------------------

Three studies\[[@B43],[@B49],[@B51]\] had data that compared successful biliary drainage in PDT group *vs* BS group. Pooled odds ratio for successful biliary drainage in PDT group *vs* BS group was 4.39 (95%CI: 2.35-8.19). *I*² (inconsistency) = 28.8% (95%CI: 0%-79.9%). Horbold-Egger: bias = -1.19 (92.5%CI: -20.32-17.94) *P =* 0.69. Figure [5](#F5){ref-type="fig"} is a forest plot of odds ratio for successful biliary drainage. Figure [6](#F6){ref-type="fig"} is an L'Abbe plot for the same variable. Bilirubin levels were assessed in all ten studies that evaluated photodynamic therapy. In the pooled study population, pre-treatment bilirubin levels (mg/dL) in PDT and BS group were 6.36 (95%CI: 5.86-6.87) and 7.83 (95%CI: 7.08-8.58) respectively. After the intervention (at median follow up period of 3months), the bilirubin levels decreased by 4.23 (95%CI: 3.86-4.60) and 2.45 (95%CI: 2.08-2.81) in PDT and BS group respectively. *I*² (inconsistency) = 97.1% (95%CI: 96.4%-97.7%). Egger: bias = 11.38 (95%CI: 5.28-17.48), *P =* 0.0026.
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![L'Abbe plot for odds ratio - successful biliary drainage in photodynamic therapy group *vs* biliary stenting group.](WJG-23-1278-g006){#F6}

Adverse events with PDT
-----------------------

Pooled odds ratio for post-intervention cholangitis episodes in PDT group *vs* BS group was 0.57 (95%CI: 0.35-0.94). *I*² (inconsistency) = 48.3% (95%CI: 0%-73.4%). Egger: bias = -0.70 (95%CI: -2.44-1.03), *P =* 0.38. Figure [7](#F7){ref-type="fig"} is a forest plot of odds ratio for cholangitis in PDT group *vs* BS group. Figure [8](#F8){ref-type="fig"} is the funnel plot for the same variable. Data regarding photosensitivity secondary to PDT was available in nine studies. One out of ten studies\[[@B45]\] did not have information on photosensitivity reactions. In the pooled proportion of patients in PDT group, 10.51% (95%CI: 6.94-14.72) had photosensitivity reactions that were self-limiting. *I*² (inconsistency) = 61.2% (95%CI: 0%-79.5%). Egger: bias = 2.81 (95%CI: 0.38-5.23) *P =* 0.02. Figure [9](#F9){ref-type="fig"} is a forest plot for photosensitivity reactions in PDT group. Due to paucity of data from the individual studies, we were unable to derive at meaningful outcomes regarding overall adverse outcomes and other individual adverse events.
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Subgroup analysis of prospective studies
----------------------------------------

Seven studies\[[@B43],[@B44],[@B46]-[@B49],[@B52]\] with 297 patients that met the inclusion criteria were included in this analysis. Median age of the patients was 68years, with 50% females. The *P* for χ^2^ heterogeneity for all the pooled accuracy estimates was \> 0.10. Pooled odds ratio for successful biliary drainage in PDT group *vs* BS group was 5.33 (95%CI: 2.71-10.50). In the pooled study population, pre-treatment bilirubin levels (mg/dL) in PDT and BS group were 5.92 (95%CI: 5.35-6.50) and 7.18 (95%CI: 6.38-7.99) respectively. After the intervention (at median follow up period of 3months), the bilirubin levels decreased by 4.35 (95%CI: 3.90-4.81) and 2.08 (95%CI: 1.70-2.45) in PDT and BS group respectively. *I*² (inconsistency) = 97.6% (95%CI: 96.8%-98.1%). In the pooled patient population, the survival period in PDT group and BS group were 420.29 (95%CI: 338.69-501.89) and 153.43 (95%CI: 109.09-197.77) respectively. *I*² (inconsistency) = 87% (95%CI: 74.2%-91.9%). The change in Karnofsky performance scores after intervention in PDT and BS groups were +7.08 (95%CI: 4.23-9.93) and -2.39 (95%CI: -2.89 to-1.89) respectively. *I*² (inconsistency) = 97.6% (95%CI: 96.7%-98.1%). Pooled odds ratio for cholangitis to be 0.78 (95%CI: 0.45-1.35) in PDT vs BS group. *I*² (inconsistency) = 45.2% (95%CI: 0%-75.3%). Photosensitivity was present in 11.59% (95%CI: 7.47-16.47) of this PDT subgroup. *I*² (inconsistency) = 69% (95%CI: 5.9%-84.1%).

DISCUSSION
==========

Cholangiocarcinoma is a rare cancer with poor prognosis. About 80% of cholangiocarcinoma present at an advanced stage and are nonresectable. Chemotherapy and radiotherapy, alone do not add any benefit to patient survival and quality of life. Effective palliation by biliary decompression to alleviate symptoms of cholestasis and prevent sepsis is the fundamental goal for most patients with nonresectable cholangiocarcinoma. PDT is a promising and evolving therapy in the management of patients with nonresectable cholangiocarcinoma. Nonresectable cholangiocarcinoma has a median survival time of 3 mo without intervention\[[@B53]\] and 4-10 mo with biliary drainage\[[@B3],[@B6],[@B7],[@B19],[@B21],[@B22],[@B53],[@B54]\]. The current systematic review and meta-analysis shows that PDT combined with biliary stenting improves the success of biliary drainage and improves the survival and quality of life in patients with nonresectable cholangiocarcinoma. For treatment of non resectable cholangiocarcinoma, photosensitizers with the ability to penetrate deep tissue are better compared to those with superficial effect. Chlorine derivatives and hematoporphyrin derivatives usually have a deep tissue penetration.

In the first RCT by Ortner et al\[[@B43]\], median survival time after PDT was 493 d compared to 98 d in patients receiving biliary stent alone. Another RCT by Zoepf et al\[[@B48]\] showed similar survival benefit in the PDT group 630 days compared to 210 d in the stent only group. Quality of life (Karnofsky index) significantly improved in the study by Ortner et al\[[@B43]\] but not in the study by Zoepf et al\[[@B48]\] due to the higher performance status of enrolled patients at study entry.

Lee et al\[[@B51]\] stated that the duration of metal stent patency was significantly longer after one session of PDT than in the stent-only group. Longer patency of metal stent by PDT translated to better quality of life by decreasing the number of procedures like stent revision or percutaneous drainage. Witzigmann et al\[[@B49]\] compared outcomes after palliative PDT and resection therapy. Their study showed that palliative PDT was inferior to complete curative (R0) resection. However, patients with palliative PDT showed similar survival time to that of patients with incomplete resection (R1/R2). Prasad et al\[[@B50]\] looked at factors associated with increased survival after PDT and found that presence of visible mass on imaging, low serum albumin and prolonged time period between diagnosis and treatment with PDT to be the predicting factors for early mortality. In non-resectable cholangiocarcinoma patients, the option of liver transplant (with eventual neo-adjuvant therapy) should be considered on a individualized basis, since this option has been studied even in patients with initially non resectable cholangiocarcinoma.

PDT was relatively well tolerated with minimal side effects in most studies. Cholangitis was the most common side effect followed by phototoxicity. All patients who had PDT also had biliary stenting. Hence cholangitis, could be a potential complication of biliary stenting as well. It is difficult to ascertain if cholangitis is a complication of PDT alone.

Strengths of this meta-analysis include the high quality methodology of statistical analysis, high quality methodology used in individual studies. This is an updated meta-analysis to pool the evidence for the utility of PDT plus biliary stenting in palliation of non resectable cholangiocarcinoma. Lu et al\[[@B55]\] was the previous meta-analysis on the topic, however several new studies were published after the first meta-analysis, that necessitated this updated analysis. Combining chemotherapy with PDT has shown survival benefit compared to PDT alone, in patients with hilar non resectable cholangiocarcinoma\[[@B56]\].

Limitations of this study are: most of the data is synthesized from studies with relatively small sample sizes. Studies differed in the method of PDT (Percutaneous or endoscopic), and the number of sessions of PDT which might have influenced the outcomes. Different types of stents (plastic *vs* metal) were used and route of stenting varied (endoscopic *vs* percutaneous transhepatic approach) among the studies, which could have all affected the outcomes. Retrospective studies were included in this meta-analysis. In order to mitigate this issue, we have performed a sub-group analysis on prospective studies only.

Studies with statistically significant positive results tend to be published and cited. Additionally, smaller studies may show larger treatment effects compared to larger studies. This publication and selection bias may affect the summary estimates. The bias can be estimated using Egger bias indicators and the construction of funnel plots, whose shape can be affected by bias. In the present meta-analysis and systematic review, bias calculations both Egger\[[@B39]\] and Begg et al\[[@B40]\] bias indicators showed no statistically significant bias. Furthermore, funnel plots were used to evaluate for publication bias among the studies included in the present analysis.

Granted there is availability of operator expertise and infrastructure availability, we believe that PDT along with biliary stenting is an excellent palliative option for non-resectable cholangiocarcinoma. Based on systematic review of literature, it is evident that in patients with resectable cholangiocarcinoma, surgery would still be the best option. The utility of PDT in this patient population (resectable cholangiocarcinoma) has not shown any additional benefit compared to surgery.

Overall, PDT combined with biliary stenting improves the success of biliary drainage and has a significant benefit in improving the survival period and quality of life. PDT is beneficial, minimally invasive, and well tolerated with a favorable side effect profile. We conclude that PDT with biliary stenting could be offered to all patients with nonresectable cholangiocarcinoma as a palliative option.
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